<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231633</url>
  </required_header>
  <id_info>
    <org_study_id>IST CRVO 1118147</org_study_id>
    <nct_id>NCT01231633</nct_id>
  </id_info>
  <brief_title>Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)</brief_title>
  <official_title>Comparative Study of Initial Ozurdex (Dexamethasone Implant) Versus Avastin (Bevacizumab) in the Treatment of Macular Edema Following Central Retinal Vein Occlusion (CRVO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Long Island Vitreoretinal Consultants</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Long Island Vitreoretinal Consultants</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare visual improvement and total number of intraocular
      injections in eyes with macular edema following central retinal vein occlusion (CRVO)after
      initial treatment with Ozurdex (dexamethasone implant) or Avastin (bevacizumab).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change in Visual Acuity (Number of ETDRS Early Treatment Diabetic Retinopathy Study Letters), at Month 6 as Compared With Baseline in Each Treatment Arm</measure>
    <time_frame>Baseline - Month 6</time_frame>
    <description>The change in visual acuity (number of ETDRS - Early Treatment Diabetic Retinopathy Study letters), at Month 6 as compared with baseline in each treatment arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Total Number of Additional Avastin Injections Following Initial Treatment in Each Treatment Arm</measure>
    <time_frame>Baseline - Month 6</time_frame>
    <description>Total Number of addiitonal Avastin injections during study- From baseline to Month 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Central Mean Thickness Based on OCT</measure>
    <time_frame>Baseline to 6 Months</time_frame>
    <description>Change in Central Mean Thickness based on OCT from baseline to Month 6t</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Macular Edema</condition>
  <condition>Central Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex</intervention_name>
    <description>Ozurdex, 0.7mg dexamethasone</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Dexamethasone implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <description>Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Avastin, bevacizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of central retinal vein occlusion (CRVO)

          -  Age 18 years or older

          -  ETDRS (Early Treatment Diabetic Retinopathy Study) Visual acuity between 3 and 72
             letters and approximate Snellen equivalent of 20/40 to 20/800

          -  OCT Central foveal thickness &gt;250 microns

          -  Negative pregnancy test for women of childbearing potential

          -  Ability to provide written informed consent

          -  Capable of complying with study protocol

        Exclusion Criteria:

          -  History of glaucoma in the study eye with intraocular pressure &gt;21mmHg on more than
             one topical medication. Combination drugs are considered more than one medication

          -  History of steroid-related glaucoma (steroid response)

          -  Previous intraocular injection of steroid medication within 90 days

          -  Avastin (bevacizumab) or Lucentis (ranibizumab) within 60 days

          -  Evidence of significant retinal ischemia on fluorescein angiography in the opinion of
             the treating physician

          -  Previous intraocular surgery (e.g. Cataract Surgery) with in 60 days

          -  Concurrent ocular disease that would limit visual acuity in the opinion of the
             treating physician

          -  Dense cataract that precludes clinical examination and retinal imaging of the retina

          -  History of allergy to dexamethasone, bevacizumab, betadine

          -  Ocular or systemic conditions that may pose a threat to the health of the subject in
             the opinion of the treating physician

          -  Unwilling or unable to follow or comply with all study related procedures

          -  Current participation in another clinical medical investigation or trial or has
             received any investigational drug within 12 weeks prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent A Deramo, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Long Island Vitreoretinal Consultants</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Vitreous Center</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Vitreoretinal Consultants</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Vitreoretinal Consultants</name>
      <address>
        <city>Hauppauge</city>
        <state>New York</state>
        <zip>11788</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Vitreoretinal Consultants</name>
      <address>
        <city>Riverhead</city>
        <state>New York</state>
        <zip>11901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2010</study_first_submitted>
  <study_first_submitted_qc>October 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2010</study_first_posted>
  <results_first_submitted>August 22, 2017</results_first_submitted>
  <results_first_submitted_qc>March 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 3, 2018</results_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Long Island Vitreoretinal Consultants</investigator_affiliation>
    <investigator_full_name>Vincent. A. Deramo, M.D.</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Macular Edema</keyword>
  <keyword>Central Retinal Vein Occlusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ozurdex &amp; Avastin</title>
          <description>Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.
Ozurdex: Ozurdex, 0.7mg dexamethasone
Avastin: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
        </group>
        <group group_id="P2">
          <title>Avastin Only</title>
          <description>Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.
Avastin: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.
Ozurdex: Ozurdex, 0.7mg dexamethasone
Avastin: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.
Avastin: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.8" lower_limit="43" upper_limit="92"/>
                    <measurement group_id="B2" value="74.3" lower_limit="62" upper_limit="86"/>
                    <measurement group_id="B3" value="71.3" lower_limit="43" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change in Visual Acuity (Number of ETDRS Early Treatment Diabetic Retinopathy Study Letters), at Month 6 as Compared With Baseline in Each Treatment Arm</title>
        <description>The change in visual acuity (number of ETDRS - Early Treatment Diabetic Retinopathy Study letters), at Month 6 as compared with baseline in each treatment arm</description>
        <time_frame>Baseline - Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.
Ozurdex: Ozurdex, 0.7mg dexamethasone
Avastin: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.
Avastin: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Visual Acuity (Number of ETDRS Early Treatment Diabetic Retinopathy Study Letters), at Month 6 as Compared With Baseline in Each Treatment Arm</title>
          <description>The change in visual acuity (number of ETDRS - Early Treatment Diabetic Retinopathy Study letters), at Month 6 as compared with baseline in each treatment arm</description>
          <units>Letters Gain/Loss</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="-7" upper_limit="38"/>
                    <measurement group_id="O2" value="16.1" lower_limit="-2" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Total Number of Additional Avastin Injections Following Initial Treatment in Each Treatment Arm</title>
        <description>Total Number of addiitonal Avastin injections during study- From baseline to Month 6</description>
        <time_frame>Baseline - Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ozurdex &amp; Avastin</title>
            <description>Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.
Ozurdex: Ozurdex, 0.7mg dexamethasone
Avastin: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
          </group>
          <group group_id="O2">
            <title>Avastin Only</title>
            <description>Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.
Avastin: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>The Total Number of Additional Avastin Injections Following Initial Treatment in Each Treatment Arm</title>
          <description>Total Number of addiitonal Avastin injections during study- From baseline to Month 6</description>
          <units>Injections</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="5.1" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Central Mean Thickness Based on OCT</title>
        <description>Change in Central Mean Thickness based on OCT from baseline to Month 6t</description>
        <time_frame>Baseline to 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.
Ozurdex: Ozurdex, 0.7mg dexamethasone
Avastin: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.
Avastin: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Central Mean Thickness Based on OCT</title>
          <description>Change in Central Mean Thickness based on OCT from baseline to Month 6t</description>
          <units>Microns on OCT</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial OCT Measure at Basline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="703" lower_limit="344" upper_limit="1255"/>
                    <measurement group_id="O2" value="790" lower_limit="496" upper_limit="1183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final OCT measure at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353" lower_limit="189" upper_limit="605"/>
                    <measurement group_id="O2" value="408" lower_limit="149" upper_limit="710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected for the study period of 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.
Ozurdex: Ozurdex, 0.7mg dexamethasone
Avastin: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.
Avastin: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vincent A. Deramo, MD</name_or_title>
      <organization>Long Island Vitreoretinal Consultants</organization>
      <phone>5164660390 ext 222</phone>
      <email>vaderamo@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

